The settlement includes all persons who purchased Ampio Pharmaceuticals Inc (NYSEMKT: AMPE) common stock from January 13, 2014 to August 21, 2014, including those who purchased Ampio Pharmaceuticals Inc (NYSEMKT: AMPE) common stock pursuant and/or traceable to the Company’s secondary public offering on or about February 28, 2014.

April 16, 2018 - The court ordered the authorization of the distribution of the net settlement fund.

September 29, 2017 - The court approved the settlement.

April 5, 2017 - The court preliminarily approved the settlement.

January 31, 2017 - Parties filed a stipulation of settlement.

September 27, 2016 - The lead plaintiff filed a second amended consolidated complaint.

August 4, 2016 - The court granted defendants' motion to dismiss without prejudice with leave to amend.

April 8, 2016 - Defendants filed a motion to dismiss.

February 8, 2016 - The lead plaintiff filed an amended consolidated complaint.

December 10, 2015 - Lead plaintiff and lead counsel were appointed and all cases were consolidated.

July 7, 2015 - Lead plaintiff motions were filed.

May 8, 2015 - An investor in shares of Ampio Pharmaceuticals Inc (NYSEMKT: AMPE) filed a lawsuit in the U.S. District Court for the Central District of California against Ampio Pharmaceuticals Inc over alleged violations of Federal Securities Laws in connection with certain allegedly false and misleading statements made between January 13, 2014 and August 21, 2014.

According to the complaint the plaintiff alleges on behalf of purchasers of Ampio Pharmaceuticals Inc (NYSEMKT: AMPE) common shares between January 13, 2014 and August 21, 2014, that the defendants violated Federal Securities Laws.

More specifically, the plaintiff claims that the clinical research organization conducting the STEP Study lacked independence, that the trial drug supply for the STEP Study was shipped to clinical sites at lower temperatures than permitted by the drug specifications, and that as a result, of the foregoing, Ampio Pharmaceuticals Inc ’s public statements were materially false and misleading at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.

Ampio Pharmaceuticals Inc reported that its annual Net Loss increased from $11.59 million in 2012 to $38.13 million in 2014. Shares of Ampio Pharmaceuticals Inc (NYSEMKT: AMPE) grew from $3.26 per share in late 2014 to as high as $8.61 per share in March 2015.

Then on April 20, 2015 Ampio Pharmaceuticals Inc announced that the multiple injection STRIDE study AP008 did not reach its primary endpoint against the saline control even though there was a statistically significant reduction in pain compared to baseline for patients receiving Ampion (WOMAC A: p < 0.001).

Shares of Ampio Pharmaceuticals Inc (NYSEMKT: AMPE) declined to as low as $2.21 per share on May 6, 2015.